BLRD Research Career Scientist Award Application

BLRD 研究职业科学家奖申请

• 批准号: 10514630
• 负责人: Maurizio Del Poeta
• 金额: --
• 依托单位: NORTHPORT VA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-10-01 至 2025-09-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10514630
• 关键词: Acquired Immunodeficiency Syndrome; Adrenal Cortex Hormones; Animal Model; Antifungal Agents; Antifungal Therapy; Aspergillus fumigatus; Autoimmune Diseases; Award; Biological Assay; Brain; CD4 Positive T Lymphocytes; Candida albicans; Cell Count; Cells; Ceramides; Cessation of life; Clinic; Clinical; Collaborations; Communicable Diseases; Communities; Containment; Cryptococcal Meningitis; Cryptococcosis; Cryptococcus; Cryptococcus neoformans; Dependence; Development; Disease; Drug Design; Drug Formulations; Drug resistance; Educational process of instructing; Effectiveness; Ensure; Environment; Enzymes; Exposure to; Faculty; Fungal Vaccines; General Population; Glucosylceramides; Goals; Granuloma; Growth; HIV; Hand; Host Defense; Immune Evasion; Immune system; Immunity; Immunocompromised Host; Industry; Infection; Injections; Inositol; Integration Host Factors; Intervention; Investigation; Knowledge; Laboratories; Lipids; Lung; Malignant Neoplasms; Mediating; Medical; Medical center; Molecular; Morbidity - disease rate; Mycoses; Organ Transplantation; Organism; Pathogenesis; Pathogenicity; Pathway interactions; Patients; Pharmaceutical Chemistry; Pharmaceutical Preparations; Phenotype; Physicians; Population; Postdoctoral Fellow; Predisposition; Preventive; Process; Research; Research Personnel; Resistance; SPHK1 enzyme; Scientist; Services; Source; South Carolina; Specificity; Sphingolipids; Sphingomyelins; Spinal Cord; Structure; Students; Substance abuse problem; Symptoms; Technology; Testing; The science of Mycology; Therapeutic; Therapeutic immunosuppression; Toxic effect; Toxicology; Training; Universities; Veterans; Virulence; Work; career; chemotherapy; cross reactivity; design; experience; fungus; high throughput screening; immunoregulation; inhibitor; interest; microbial; microorganism interaction; military service; mortality; multiple sclerosis treatment; novel; novel therapeutic intervention; novel therapeutics; opportunistic pathogen; patient population; research and development; small molecule; sphingomyelin synthase; sphingosine 1-phosphate; therapeutically effective

ABSTRACT I am an Infectious Diseases physician-scientist with over 28 years of experience in medical mycology. During my career, I have been working in the clinic and at the bench, teaching and training many students, post-docs and junior faculty at Duke University, the Medical University of South Carolina, and now at Stony Brook University and at the Northport VA Medical Center. My overall career goal is to bring a new antifungal in the clinic, and I am closer than ever with MicroRid Technologies Inc., a start-up company I co-founded for the research and development of new antifungal drugs. My laboratory pioneered the studies on lipid-mediated infectious diseases. My lab and my co-workers reached such a high visibility in this field that we are continuously contacted for consultant work by investigators from all over the world for lipid analysis in their favorite organisms. My studies have mostly focused on fungal infections, particularly invasive fungal infections, because they are on the rise in our Veterans and in our non-Veterans populations. As we live longer thanks to many benefits of chemo- and immunosuppressive-therapies and organ transplantations, we are also facing a rise of invasive fungal infectious diseases. Current antifungals are either fungistatic, toxic, with narrow spectrum of activity or they become resistant. New treatment strategies are needed. In addition to develop a new class of antifungal agents, the studies in my laboratory are also crucial to the understanding of the host mechanisms required for fungal containment versus fungal dissemination and disease. For these studies, I partnered with many collaborators at the VA medical centers, at various Universities, and at the industry setting, establishing fruitful and successful collaborations. The VA RCS award will allow our group to continue this great work and will provide stability to fulfill the current goals and to start new research directions. The RCS Award will also allow me to broaden my collaborative research even further, particularly with the VA physicians involved in the MVP, enhancing my research clinical enterprise, and to continue my service to the scientific community at the VA and beyond.

摘要 我是一名传染病医生，科学家，在医学真菌学方面有超过28年的经验。 在我的职业生涯中，我一直在诊所和替补席上工作，教学和培训许多人 杜克大学、南卡罗来纳州医科大学的学生、博士后和初级教师， 现在在斯托尼布鲁克大学和北港退伍军人医疗中心。我的职业目标是 将一种新的抗真菌药物引入临床，我比以往任何时候都更接近MicroRid技术公司，一 这是一家我与人共同创立的初创公司，专门研究和开发新型抗真菌药物。 我的实验室是研究脂质介导的传染病的先驱。我的实验室和同事 在这一领域达到了如此高的知名度，我们不断联系咨询工作， 来自世界各地的研究人员在他们最喜欢的生物体中进行脂质分析。我的研究 主要集中在真菌感染，特别是侵袭性真菌感染，因为他们是在 在我们的退伍军人和非退伍军人群体中崛起。我们的寿命更长，这要归功于 化疗和免疫抑制疗法以及器官移植，我们也面临着 侵袭性真菌感染性疾病目前的抗真菌药物要么是抑制真菌的，有毒的， 或者他们变得有抵抗力。需要新的治疗策略。除了 开发一类新的抗真菌药物，我实验室的研究也是至关重要的， 了解真菌控制与真菌传播所需的宿主机制 和疾病对于这些研究，我与VA医疗中心的许多合作者合作， 在不同的大学，并在行业设置，建立富有成效的和成功的合作。的 VA RCS奖将使我们的小组继续这项伟大的工作，并将提供稳定，以履行 目前的目标，并开始新的研究方向。RCS奖也将让我扩大我的 进一步的合作研究，特别是与参与MVP的VA医生， 加强我的临床研究事业，并继续为科学界服务， VA和超越。